Previous 10 | Next 10 |
2024-04-28 08:00:00 ET As the calendar flips from April to May, the upcoming week is set to bring a flurry of earnings reports from some of the world's most prominent companies. At the top of the list, updates are anticipated from tech giants Amazon ( NASDAQ: AMZN ) and Apple ( NA...
2024-04-27 14:11:33 ET More on Pfizer Unveiling Pfizer's Potent Cocktail: Key Drivers Of Free Cash Flow Growth Pfizer's Doldrums, Just A Bad Case Of COVID-19? Pfizer Eyeing Viking Therapeutics? A Scenario Among All The M&A Talk Pfizer gets FDA approval fo...
2024-04-26 04:50:00 ET Moderna (NASDAQ: MRNA) stock soared earlier in the pandemic as the company developed its coronavirus vaccine and the product went on to generate billions of dollars in sales. But as demand for the vaccine declined, Moderna stock followed. Investors are worried...
2024-04-25 10:56:02 ET More on GSK GSK Trades At Low Price Multiples, But Its Pipeline Needs To Improve GSK plc (GSK) TD Cowen 44th Annual Health Care Conference (Transcript) GSK Plc: An Undervalued Vaccine Behemoth That Is Resuming Growth; Buy Sanofi reporte...
CAMBRIDGE, MA / ACCESSWIRE / April 25, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present data from its respiratory portfolio, including vaccines and vaccine candidates against COVID-19 (mRNA-1273, mRNA-1283), influenza (mRNA-1010, mRNA-1011/1012), and respiratory s...
2024-04-24 09:19:50 ET More on Moderna Moderna Investors Should Beware Patent-Dispute Fallout Moderna: Considering The Cancer Vaccine Angle Moderna Continues To Build A Pipeline S&P 500 stocks with biggest estimated EPS declines for Q1 Moderna sto...
Generative AI will help advance Moderna's broad and diverse portfolio to maximize the Company's impact on patients Moderna embeds OpenAI's generative AI tools throughout its organization and sees early success with broad adoption of ChatGPT Enterprise CAMBRIDGE, MA AND SAN FRANCISCO, CA ...
2024-04-23 14:40:54 ET Summary Moderna's stock rose after positive results from its cancer vaccine trial, but legal issues could lead to a massive judgment against the company. Moderna is facing a patent dispute over its use of lipid nanoparticles technology without proper licensi...
2024-04-23 12:33:52 ET Moderna ( NASDAQ: MRNA ), Ventas ( NYSE: VTR ) and American Airlines ( NASDAQ: AAL ) are among the S&P 500 companies with the greatest expected Y/Y decreases in EPS for the first quarter, according to the latest from S&P Globa...
2024-04-22 16:01:53 ET Read the full article on Seeking Alpha For further details see: Moderna stock closes in green after eight sessions of losses
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...